REVIEW
Epigenetic Modifications in HBV-Related Hepatocellular Carcinoma
Xiaoqing Tan,
Linting Xun,
Qi Yin,
Chaohui Chen,
Tao Zhang,
Tao Shen,
Xiaoqing Tan
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, Peoples republic of China, China
Search for more papers by this authorLinting Xun
Department of Gastroenterology, the First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, People's Republic of China
Search for more papers by this authorQi Yin
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, People's Republic of China, China
Search for more papers by this authorChaohui Chen
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Search for more papers by this authorTao Zhang
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, Peoples republic of China, China
Search for more papers by this authorCorresponding Author
Tao Shen
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, Peoples republic of China, China
Correspondence:
Tao Shen ([email protected])
Search for more papers by this authorXiaoqing Tan,
Linting Xun,
Qi Yin,
Chaohui Chen,
Tao Zhang,
Tao Shen,
Xiaoqing Tan
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, Peoples republic of China, China
Search for more papers by this authorLinting Xun
Department of Gastroenterology, the First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, People's Republic of China
Search for more papers by this authorQi Yin
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, People's Republic of China, China
Search for more papers by this authorChaohui Chen
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Search for more papers by this authorTao Zhang
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, Peoples republic of China, China
Search for more papers by this authorCorresponding Author
Tao Shen
Medical School, Kunming University of Science and Technology, Kunming, People's Republic of China
Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province, Kunming, Peoples republic of China, China
Correspondence:
Tao Shen ([email protected])
Search for more papers by this authorFunding: This work is supported by the National Natural Science Foundation of China (82160384 and 82260395), in part by the Yunnan Health Commission (L2019003), and in part by the Yunnan Provincial Science and Technology Department (2019FA030 and 202205AG070061).
Linting Xun and Xiaoqing Tan is contributed equally to this work.
ABSTRACT
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatitis B virus (HBV) is the main pathogen for HCC development. HBV covalently closed circular DNA (cccDNA) forms extra-host chromatin-like minichromosomes in the nucleus of hepatocytes with host histones, non-histones, HBV X protein (HBx) and HBV core protein (HBc). Epigenetic alterations are dynamic and reversible, which regulate gene expression without altering the DNA sequence and play a pivotal role in the regulation of HCC onset and progression. The aim of this review is to elucidate the deregulation of epigenetic mechanisms involved in the pathogenesis of HBV-related HCC (HBV-HCC), including post-translational histone and non-histone modifications, DNA hypermethylation and hypomethylation, non-coding RNA modification on HBV cccDNA minichromosomes and host factors, effecting the replication/transcription of HBV cccDNA and transcription/translation of host genes, and thus HBV-HCC progression. It is expected that the epigenetic regulation perspective provides new ways for more in-depth development of therapeutic control of HBV-HCC.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians (2024).
- 2G. P. Nagaraju, B. Dariya, P. Kasa, S. Peela, and B. F. El-Rayes, “Epigenetics in Hepatocellular Carcinoma,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 622–632.
- 3F. Chik, M. Szyf, and S. A. Rabbani, “Role of Epigenetics in Cancer Initiation and Progression,” Advances in Experimental Medicine and Biology 720 (2011): 91–104.
- 4Y. Alaghband, T. W. Bredy, and M. A. Wood, “The Role of Active DNA Demethylation and Tet Enzyme Function in Memory Formation and Cocaine Action,” Neuroscience Letters 625 (2016): 40–46.
- 5N. K. Yu, S. H. Baek, and B. K. Kaang, “DNA Methylation-Mediated Control of Learning and Memory,” Molecular Brain 4 (2011): 5.
- 6P. A. Jones and G. Liang, “Rethinking How DNA Methylation Patterns Are Maintained,” Nature Reviews. Genetics 10, no. 11 (2009): 805–811.
- 7M. G. Fernández-Barrena, M. Arechederra, L. Colyn, C. Berasain, and M. A. Avila, “Epigenetics in Hepatocellular Carcinoma Development and Therapy: The Tip of the Iceberg,” JHEP Reports 2, no. 6 (2020): 100167.
- 8C. D. Allis and T. Jenuwein, “The Molecular Hallmarks of Epigenetic Control,” Nature Reviews. Genetics 17, no. 8 (2016): 487–500.
- 9S. Pan and R. Chen, “Pathological Implication of Protein Post-Translational Modifications in Cancer,” Molecular Aspects of Medicine 86 (2022): 101097.
- 10J. C. Eissenberg and A. Shilatifard, “Histone H3 lysine 4 (H3K4) Methylation in Development and Differentiation,” Developmental Biology 339, no. 2 (2010): 240–249.
- 11E. L. Greer and Y. Shi, “Histone Methylation: A Dynamic Mark in Health, Disease and Inheritance,” Nature Reviews Genetics 13, no. 5 (2012): 343–357.
- 12T. Kouzarides, “Chromatin Modifications and Their Function,” Cell 128, no. 4 (2007): 693–705.
- 13M. D. Shahbazian and M. Grunstein, “Functions of Site-Specific Histone Acetylation and Deacetylation,” Annual Review of Biochemistry 76 (2007): 75–100.
- 14G. Milazzo, D. Mercatelli, G. Di Muzio, et al., “Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability,” Genes (Basel) 11, no. 5 (2020).
- 15F. A. Verza, U. Das, A. L. Fachin, J. R. Dimmock, and M. Marins, “Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy,” Cancers (Basel) 12, no. 6 (2020).
- 16L. Che, Z. B. Du, W. H. Wang, et al., “Intracellular Antibody Targeting HBx Suppresses Invasion and Metastasis in Hepatitis B Virus-Related Hepatocarcinogenesis Via Protein Phosphatase 2A-B56γ-Mediated Dephosphorylation of Protein Kinase B,” Cell Proliferation 55, no. 11 (2022): e13304.
- 17Z. Zhao and A. Shilatifard, “Epigenetic Modifications of Histones in Cancer,” Genome Biology 20, no. 1 (2019): 245.
- 18D. Yin, N. Jiang, Y. Zhang, et al., “Global Lysine Crotonylation and 2-Hydroxyisobutyrylation in Phenotypically Different Toxoplasma Gondii Parasites,” Molecular & Cellular Proteomics 18, no. 11 (2019): 2207–2224.
- 19M. D. Hirschey and Y. Zhao, “Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation,” Molecular & Cellular Proteomics 14, no. 9 (2015): 2308–2315.
- 20Z. Zhang, M. Tan, Z. Xie, L. Dai, Y. Chen, and Y. Zhao, “Identification of Lysine Succinylation as a New Post-Translational Modification,” Nature Chemical Biology 7, no. 1 (2011): 58–63.
- 21L. Zhao, M. Kang, X. Liu, et al., “UBR7 Inhibits HCC Tumorigenesis by Targeting Keap1/Nrf2/Bach1/HK2 and Glycolysis,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 330.
- 22J. Kim, M. Guermah, R. K. McGinty, et al., “RAD6-Mediated Transcription-Coupled H2B Ubiquitylation Directly Stimulates H3K4 Methylation in Human Cells,” Cell 137, no. 3 (2009): 459–471.
- 23M. G. Martinez, A. Boyd, E. Combe, B. Testoni, and F. Zoulim, “Covalently Closed Circular DNA: The Ultimate Therapeutic Target for Curing HBV Infections,” Journal of Hepatology 75, no. 3 (2021): 706–717.
- 24M. Quasdorff and U. Protzer, “Control of Hepatitis B Virus at the Level of Transcription,” Journal of Viral Hepatitis 17, no. 8 (2010): 527–536.
- 25M. Dandri, “Epigenetic Modulation in Chronic Hepatitis B Virus Infection,” Seminars in Immunopathology 42, no. 2 (2020): 173–185.
- 26S. R. N. Sudhakar, S. N. Khan, A. Clark, et al., “Protein Arginine Methyltransferase 1, a Major Regulator of Biological Processes,” Biochemistry and Cell Biology 102, no. 2 (2024): 106–126.
- 27S. Huang, M. Litt, and G. Felsenfeld, “Methylation of Histone H4 by Arginine Methyltransferase PRMT1 is Essential in Vivo for Many Subsequent Histone Modifications,” Genes & Development 19, no. 16 (2005): 1885–1893.
- 28S. Benhenda, A. Ducroux, L. Rivière, et al., “Methyltransferase PRMT1 is a Binding Partner of HBx and a Negative Regulator of Hepatitis B Virus Transcription,” Journal of Virology 87, no. 8 (2013): 4360–4371.
- 29W. Zhang, J. Chen, M. Wu, et al., “PRMT5 Restricts Hepatitis B Virus Replication Through Epigenetic Repression of Covalently Closed Circular DNA Transcription and Interference with Pregenomic RNA Encapsidation,” Hepatology 66, no. 2 (2017): 398–415.
- 30G. Yang, J. Feng, Y. Liu, et al., “HAT1 Signaling Confers to Assembly and Epigenetic Regulation of HBV cccDNA Minichromosome,” Theranostics 9, no. 24 (2019): 7345–7358.
- 31T. Pollicino, L. Belloni, G. Raffa, et al., “Hepatitis B Virus Replication is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones,” Gastroenterology 130, no. 3 (2006): 823–837.
- 32F. Wei and D. Meng, “Study on the Role of Histone Epigenetic Modification in Replication of Hepatitis B Virus,” Biochemical and Biophysical Research Communications 669 (2023): 1–9.
- 33L. N. Zhao, H. F. Yuan, Y. F. Wang, et al., “IFN-α Inhibits HBV Transcription and Replication by Promoting HDAC3-Mediated de-2-Hydroxyisobutyrylation of Histone H4K8 on HBV cccDNA Minichromosome in Liver,” Acta Pharmacologica Sinica 43, no. 6 (2022): 1484–1494.
- 34J. H. Ren, J. L. Hu, S. T. Cheng, et al., “SIRT3 Restricts Hepatitis B Virus Transcription and Replication Through Epigenetic Regulation of Covalently Closed Circular DNA Involving Suppressor of Variegation 3-9 Homolog 1 and SET Domain Containing 1A Histone Methyltransferases,” Hepatology 68, no. 4 (2018): 1260–1276.
- 35Y. Yuan, K. Zhao, Y. Yao, et al., “HDAC11 Restricts HBV Replication Through Epigenetic Repression of cccDNA Transcription,” Antiviral Research 172 (2019): 104619.
- 36Y. Wang, M. Han, S. Liu, et al., “S6K1 Inhibits HBV Replication Through Inhibiting AMPK-ULK1 Pathway and Disrupting Acetylation Modification of H3K27,” Life Sciences 265 (2021): 118848.
- 37X. Yu, Q. Long, S. Shen, et al., “Screening of an Epigenetic Compound Library Identifies BRD4 as a Potential Antiviral Target for Hepatitis B Virus Covalently Closed Circular DNA Transcription,” Antiviral Research 211 (2023): 105552.
- 38Z. Q. Wei, Y. H. Zhang, C. Z. Ke, et al., “Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation,” World Journal of Gastroenterology 23, no. 34 (2017): 6252–6260.
- 39Z. Z. Piracha, U. Saeed, J. Kim, et al., “An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases,” Journal of Virology 94, no. 16 (2020).
- 40Y. Yuan, H. Yuan, G. Yang, et al., “IFN-α Confers Epigenetic Regulation of HBV cccDNA Minichromosome by Modulating GCN5-Mediated Succinylation of Histone H3K79 to Clear HBV cccDNA,” Clinical Epigenetics 12, no. 1 (2020): 135.
- 41Y. P. Qin, H. B. Yu, S. Y. Yuan, et al., “KAT2A Promotes Hepatitis B Virus Transcription and Replication Through Epigenetic Regulation of cccDNA Minichromosome,” Frontiers in Microbiology 12 (2021): 795388.
- 42H. B. Yu, S. T. Cheng, F. Ren, et al., “SIRT7 Restricts HBV Transcription and Replication Through Catalyzing Desuccinylation of Histone H3 Associated with cccDNA Minichromosome,” Clinical Science (London, England) 135, no. 12 (2021): 1505–1522.
- 43Y. Sun, Y. Teng, L. Wang, et al., “LINC01431 Promotes Histone H4R3 Methylation to Impede HBV Covalently Closed Circular DNA Transcription by Stabilizing PRMT1,” Advanced Science (Weinh) 9, no. 16 (2022): e2103135.
- 44J. Feng, G. Yang, Y. Liu, et al., “LncRNA PCNAP1 Modulates Hepatitis B Virus Replication and Enhances Tumor Growth of Liver Cancer,” Theranostics 9, no. 18 (2019): 5227–5245.
- 45Y. Liu, J. Feng, M. Sun, et al., “Long Non-Coding RNA HULC Activates HBV by Modulating HBx/STAT3/miR-539/APOBEC3B Signaling in HBV-Related Hepatocellular Carcinoma,” Cancer Letters 454 (2019): 158–170.
- 46D. Salerno, L. Chiodo, V. Alfano, et al., “Hepatitis B Protein HBx Binds the DLEU2 lncRNA to Sustain cccDNA and Host Cancer-Related Gene Transcription,” Gut 69, no. 11 (2020): 2016–2024.
- 47X. Zhang, Y. Li, C. Huan, et al., “LncRNA NKILA Inhibits HBV Replication by Repressing NF-κB Signalling Activation,” Virologica Sinica 39, no. 1 (2024): 44–55.
- 48I. Y. Moon, J. H. Choi, J. W. Chung, E. S. Jang, S. H. Jeong, and J. W. Kim, “MicroRNA‑20 Induces Methylation of Hepatitis B Virus Covalently Closed Circular DNA in Human Hepatoma Cells,” Molecular Medicine Reports 20, no. 3 (2019): 2285–2293.
- 49P. Vivekanandan, D. Thomas, and M. Torbenson, “Methylation Regulates Hepatitis B Viral Protein Expression,” Journal of Infectious Diseases 199, no. 9 (2009): 1286–1291.
- 50H. Lee, H. Jeong, S. Y. Lee, S. S. Kim, and K. L. Jang, “Hepatitis B Virus X Protein Stimulates Virus Replication Via DNA Methylation of the C-1619 in Covalently Closed Circular DNA,” Molecules and Cells 42, no. 1 (2019): 67–78.
- 51H. Yuan, L. Zhao, Y. Yuan, et al., “HBx Represses WDR77 to Enhance HBV Replication by DDB1-Mediated WDR77 Degradation in the Liver,” Theranostics 11, no. 17 (2021): 8362–8378.
- 52W. Gao, Z. Jia, Y. Tian, et al., “HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein,” Hepatology 71, no. 5 (2020): 1678–1695.
- 53E. S. Kim, J. Zhou, H. Zhang, et al., “Hepatitis B Virus X Protein Counteracts High Mobility Group Box 1 Protein-Mediated Epigenetic Silencing of Covalently Closed Circular DNA,” PLoS Pathogens 18, no. 6 (2022): e1010576.
- 54Y. Zhang, C. Li, Y. Zhang, et al., “Comparative Analysis of CpG Islands Among HBV Genotypes,” PLoS One 8, no. 2 (2013): e56711.
- 55Y. Guo, Y. Li, S. Mu, J. Zhang, and Z. Yan, “Evidence that Methylation of Hepatitis B Virus Covalently Closed Circular DNA in Liver Tissues of Patients with Chronic Hepatitis B Modulates HBV Replication,” Journal of Medical Virology 81, no. 7 (2009): 1177–1183.
- 56S. Murakami, “Hepatitis B Virus X Protein: A Multifunctional Viral Regulator,” Journal of Gastroenterology 36, no. 10 (2001): 651–660.
- 57J. O. Lee, H. J. Kwun, J. K. Jung, K. H. Choi, D. S. Min, and K. L. Jang, “Hepatitis B Virus X Protein Represses E-Cadherin Expression Via Activation of DNA Methyltransferase 1,” Oncogene 24, no. 44 (2005): 6617–6625.
- 58Y. Yan, P. Huang, K. Mao, et al., “Anti-Oncogene PTPN13 Inactivation by Hepatitis B Virus X Protein Counteracts IGF2BP1 to Promote Hepatocellular Carcinoma Progression,” Oncogene 40, no. 1 (2021): 28–45.
- 59I. Y. Park, B. H. Sohn, E. Yu, et al., “Aberrant Epigenetic Modifications in Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein,” Gastroenterology 132, no. 4 (2007): 1476–1494.
- 60S. Hofmann, V. Plank, P. Groitl, et al., “SUMO Modification of Hepatitis B Virus Core Mediates Nuclear Entry, Promyelocytic Leukemia Nuclear Body Association, and Efficient Formation of Covalently Closed Circular DNA,” Microbiology Spectrum 11, no. 3 (2023): e0044623.
- 61J. Xi, L. Luckenbaugh, and J. Hu, “Multiple Roles of PP2A Binding Motif in Hepatitis B Virus Core Linker and PP2A in Regulating Core Phosphorylation State and Viral Replication,” PLoS Pathogens 17, no. 1 (2021): e1009230.
- 62J. Luo, J. Xi, L. Gao, and J. Hu, “Role of Hepatitis B Virus Capsid Phosphorylation in Nucleocapsid Disassembly and Covalently Closed Circular DNA Formation,” PLoS Pathogens 16, no. 3 (2020): e1008459.
- 63C. Lefeuvre, H. Le Guillou-Guillemette, and A. Ducancelle, “A Pleiotropic Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis,” International Journal of Molecular Sciences 22, no. 24 (2021).
- 64B. Mitra, R. J. Thapa, H. Guo, and T. M. Block, “Host Functions Used by Hepatitis B Virus to Complete Its Life Cycle: Implications for Developing Host-Targeting Agents to Treat Chronic Hepatitis B,” Antiviral Research 158 (2018): 185–198.
- 65J. Li, G. Duns, H. Westers, R. Sijmons, A. van den Berg, and K. Kok, “SETD2: An Epigenetic Modifier with Tumor Suppressor Functionality,” Oncotarget 7, no. 31 (2016): 50719–50734.
- 66K. Chen, J. Liu, S. Liu, et al., “Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interferon Antiviral Activity,” Cell 170, no. 3 (2017): 492–506.e414.
- 67C. M. Wong, L. Wei, C. T. Law, et al., “Up-Regulation of Histone Methyltransferase SETDB1 by Multiple Mechanisms in Hepatocellular Carcinoma Promotes Cancer Metastasis,” Hepatology 63, no. 2 (2016): 474–487.
- 68Y. Zhang, W. Lao, K. Yang, et al., “SUV39H1 is a Novel Biomarker Targeting Oxidative Phosphorylation in Hepatitis B Virus-Associated Hepatocellular Carcinoma,” BMC Cancer 23, no. 1 (2023): 1159.
- 69D. N. Fan, F. H. Tsang, A. H. Tam, et al., “Histone Lysine Methyltransferase, Suppressor of Variegation 3-9 Homolog 1, Promotes Hepatocellular Carcinoma Progression and is Negatively Regulated by Microrna-125b,” Hepatology 57, no. 2 (2013): 637–647.
- 70L. T. Yuan, W. J. Lee, Y. C. Yang, et al., “Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122,” Cancers (Basel) 13, no. 10 (2021).
- 71L. Wei, D. K. Chiu, F. H. Tsang, et al., “Development by Epigenetic Silencing of Tumor Suppressor Gene RARRES3,” Journal of Hepatology 67, no. 4 (2017): 758–769.
- 72M. Li, Y. Deng, M. Zhuo, et al., “Demethylase-Independent Function of JMJD2D as a Novel Antagonist of p53 to Promote Liver Cancer Initiation and Progression,” Theranostics 10, no. 19 (2020): 8863–8879.
- 73Y. Deng, M. Li, M. Zhuo, et al., “Histone Demethylase JMJD2D Promotes the Self-Renewal of Liver Cancer Stem-Like Cells by Enhancing EpCAM and Sox9 Expression,” Journal of Biological Chemistry 296 (2021): 100121.
- 74Q. Lin, Z. Wu, X. Yue, et al., “ZHX2 Restricts Hepatocellular Carcinoma by Suppressing Stem Cell-Like Traits Through KDM2A-Mediated H3K36 Demethylation,” eBioMedicine 53 (2020): 102676.
- 75S. L. Au, C. C. Wong, J. M. Lee, C. M. Wong, and I. O. Ng, “EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers,” PLoS One 8, no. 6 (2013): e68226.
- 76S. L. Au, C. C. Wong, J. M. Lee, et al., “Enhancer of Zeste Homolog 2 Epigenetically Silences Multiple Tumor Suppressor microRNAs to Promote Liver Cancer Metastasis,” Hepatology 56, no. 2 (2012): 622–631.
- 77N. Poté, J. Cros, S. Laouirem, et al., “The Histone Acetyltransferase hMOF Promotes Vascular Invasion in Hepatocellular Carcinoma,” Liver International 40, no. 4 (2020): 956–967.
- 78S. Wei, W. Liu, N. Sun, et al., “MOF Upregulates the Estrogen Receptor α Signaling Pathway by Its Acetylase Activity in Hepatocellular Carcinoma,” Cancer Science 112, no. 5 (2021): 1865–1877.
- 79J. Xue, Z. Cao, Y. Cheng, et al., “Acetylation of Alpha-Fetoprotein Promotes Hepatocellular Carcinoma Progression,” Cancer Letters 471 (2020): 12–26.
- 80Z. Huang, J. Zhao, W. Deng, et al., “Identification of a Cellularly Active SIRT6 Allosteric Activator,” Nature Chemical Biology 14, no. 12 (2018): 1118–1126.
- 81M. Yanai, M. Kurata, Y. Muto, et al., “Clinicopathological and Molecular Analysis of SIRT7 in Hepatocellular Carcinoma,” Pathology 52, no. 5 (2020): 529–537.
- 82J. Zhao, A. Wozniak, A. Adams, et al., “SIRT7 Regulates Hepatocellular Carcinoma Response to Therapy by Altering the p53-Dependent Cell Death Pathway,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 252.
- 83J. Niu, W. Li, C. Liang, et al., “EGF Promotes DKK1 Transcription in Hepatocellular Carcinoma by Enhancing the Phosphorylation and Acetylation of Histone H3,” Science Signaling 13, no. 657 (2020): eabb5727.
- 84F. Wang, W. Zhao, Y. Gao, et al., “CDK5-Mediated Phosphorylation and Stabilization of TPX2 Promotes Hepatocellular Tumorigenesis,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 286.
- 85W. Chen, W. Yang, C. Zhang, et al., “Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma Through Phosphorylation of H3S10,” Oxidative Medicine and Cellular Longevity 2022 (2022): 6986445.
- 86W. Li, Q. Han, Y. Zhu, et al., “SUMOylation of RNF146 Results in Axin Degradation and Activation of Wnt/β-Catenin Signaling to Promote the Progression of Hepatocellular Carcinoma,” Oncogene 42, no. 21 (2023): 1728–1740.
- 87S. T. Yang, C. J. Yen, C. H. Lai, et al., “SUMOylated CPAP is Required for IKK-Mediated NF-κB Activation and Enhances HBx-Induced NF-κB Signaling in HCC,” Journal of Hepatology 58, no. 6 (2013): 1157–1164.
- 88Z. Yang, C. Yan, J. Ma, et al., “Lactylome Analysis Suggests Lactylation-Dependent Mechanisms of Metabolic Adaptation in Hepatocellular Carcinoma,” Nature Metabolism 5, no. 1 (2023): 61–79.
- 89H. Zhang, A. Diab, H. Fan, et al., “PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 During Hepatitis B Virus-Induced Liver Carcinogenesis,” Cancer Research 75, no. 11 (2015): 2363–2374.
- 90L. Tao, D. Li, S. Mu, G. Tian, and G. Yan, “LncRNA MAPKAPK5_AS1 Facilitates Cell Proliferation in Hepatitis B Virus -Related Hepatocellular Carcinoma,” Laboratory Investigation 102, no. 5 (2022): 494–504.
- 91Y. Deng, Z. Wei, M. Huang, et al., “Long Non-Coding RNA F11-AS1 Inhibits HBV-Related Hepatocellular Carcinoma Progression by Regulating NR1I3 Via Binding to microRNA-211-5p,” Journal of Cellular and Molecular Medicine 24, no. 2 (2020): 1848–1865.
- 92H. He, J. Zhou, F. Cheng, H. Li, and Y. Quan, “MiR-3677-3p Promotes Development and Sorafenib Resistance of Hepatitis B-Related Hepatocellular Carcinoma by Inhibiting FOXM1 Ubiquitination,” Human Cell 36, no. 5 (2023): 1773–1789.
- 93H. H. Liu, Y. Fang, J. W. Wang, et al., “Hypomethylation of the Cyclin D1 Promoter in Hepatitis B Virus-Associated Hepatocellular Carcinoma,” Medicine (Baltimore) 99, no. 20 (2020): e20326.
- 94L. Xiong, F. Wu, Q. Wu, et al., “Aberrant Enhancer Hypomethylation Contributes to Hepatic Carcinogenesis Through Global Transcriptional Reprogramming,” Nature Communications 10, no. 1 (2019): 335.
- 95L. Xiang, L. M. Chen, Y. J. Zhai, et al., “Hypermethylation of Secreted Frizzled Related Protein 2 Gene Promoter Serves as a Noninvasive Biomarker for HBV-Associated Hepatocellular Carcinoma,” Life Sciences 270 (2021): 119061.
- 96D. Sun, X. Gan, L. Liu, et al., “DNA Hypermethylation Modification Promotes the Development of Hepatocellular Carcinoma by Depressing the Tumor Suppressor Gene ZNF334,” Cell Death & Disease 13, no. 5 (2022): 446.
- 97J. Kwon, Y. V. Liu, C. Gao, et al., “Pseudogene-Mediated DNA Demethylation Leads to Oncogene Activation,” Science Advances 7, no. 40 (2021): eabg1695.
- 98X. Song, S. Tan, Z. Wu, et al., “HBV Suppresses ZHX2 Expression to Promote Proliferation of HCC Through miR-155 Activation,” International Journal of Cancer 143, no. 12 (2018): 3120–3130.
- 99Q. Wang, S. T. Cheng, and J. Chen, “HBx Mediated Increase of SIRT1 Contributes to HBV-Related Hepatocellular Carcinoma Tumorigenesis,” International Journal of Medical Sciences 17, no. 12 (2020): 1783–1794.
- 100D. Rossetto, N. Avvakumov, and J. Cote, “Histone Phosphorylation: A Chromatin Modification Involved in Diverse Nuclear Events,” Epigenetics 7, no. 10 (2012): 1098–1108.
- 101S. M. Ehrlich, J. Liebl, M. A. Ardelt, et al., “Targeting Cyclin Dependent Kinase 5 in Hepatocellular Carcinoma--A Novel Therapeutic Approach,” Journal of Hepatology 63, no. 1 (2015): 102–113.
- 102M. L. Tomasi and K. Ramani, “SUMOylation and Phosphorylation Cross-Talk in Hepatocellular Carcinoma,” Translational Gastroenterology and Hepatology 3 (2018): 20.
- 103M. Zeng, W. Liu, Y. Hu, and N. Fu, “Sumoylation in Liver Disease,” Clinica Chimica Acta 510 (2020): 347–353.
- 104Y. F. Su, Y. C. Shyu, C. K. Shen, and J. Hwang, “Phosphorylation-Dependent SUMOylation of the Transcription Factor NF-E2,” PLoS One 7, no. 9 (2012): e44608.
- 105M. Koyanagi, M. Hijikata, K. Watashi, O. Masui, and K. Shimotohno, “Centrosomal P4.1-Associated Protein is a New Member of Transcriptional Coactivators for Nuclear Factor-kappaB,” Journal of Biological Chemistry 280, no. 13 (2005): 12430–12437.
- 106X. Yu and Z. Li, “Long Non-Coding RNA HOTAIR: A Novel Oncogene (Review),” Molecular Medicine Reports 12, no. 4 (2015): 5611–5618.
- 107J. Liu, J. Jiang, J. Mo, et al., “Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma,” Hepatology 69, no. 1 (2019): 196–208.
- 108C. Ozen, G. Yildiz, A. T. Dagcan, et al., “Genetics and Epigenetics of Liver Cancer,” New Biotechnology 30, no. 4 (2013): 381–384.
- 109J. R. Yang, J. Wang, H. M. Li, S. Gao, Y. C. Fan, and K. Wang, “IL-6 Promoter Hypomethylation Acts as a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma,” Frontiers in Oncology 12 (2022): 746643.
- 110P. Pastras, E. Zazas, M. Kalafateli, et al., “Predictive Risk Factors and Scoring Systems Associated with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B,” Cancers (Basel) 16, no. 14 (2024).
- 111Y. Xu, C. Xia, H. Li, et al., “Survey of Hepatitis B Virus Infection for Liver Cancer Screening in China: A Population-Based, Cross-Sectional Study,” Chinese Medical Journal 137, no. 12 (2024): 1414–1420.
- 112M. H. Lee, Y. T. Chen, Y. H. Huang, et al., “Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC,” Clinical Gastroenterology and Hepatology 22, no. 6 (2024): 1275–1285.e1272.
- 113G. Ferreira, A. L. Stuurman, Y. Horsmans, et al., “Hepatitis B Virus Infection and the Risk of Liver Disease Progression in Type 2 Diabetic Patients with Potential Nonalcoholic Fatty Liver Disease: A Retrospective, Observational, Cohort Study in the United Kingdom Clinical Practice Research Datalink,” European Journal of Gastroenterology & Hepatology 32, no. 1 (2020): 101–109.
- 114T. Cheuk-Fung Yip, V. Wai-Sun Wong, H. Lik-Yuen Chan, et al., “Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen,” Clinical Gastroenterology and Hepatology 16, no. 5 (2018): 765–773.e762.
- 115X. Li, H. Xu, and P. Gao, “Diabetes Mellitus is a Risk Factor for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection in China,” Medical Science Monitor 24 (2018): 6729–6734.
- 116F. P. Cossío, M. Esteller, and M. Berdasco, “Towards a More Precise Therapy in Cancer: Exploring Epigenetic Complexity,” Current Opinion in Chemical Biology 57 (2020): 41–49.
- 117L. Gailhouste, L. C. Liew, K. Yasukawa, et al., “Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells,” Molecular Therapy 26, no. 7 (2018): 1840–1854.
- 118Y. Wei, X. M. Lao, X. Xiao, et al., “Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice,” Gastroenterology 156, no. 6 (2019): 1890–1904.e1816.
- 119Z. Yang, S. Gao, C. C. Wong, et al., “TUBB4B is a Novel Therapeutic Target in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma,” Journal of Pathology 260, no. 1 (2023): 71–83.
- 120M. Bárcena-Varela, S. Caruso, S. Llerena, et al., “Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma,” Hepatology 69, no. 2 (2019): 587–603.
- 121X. Wan, K. Wisskirchen, T. Jin, et al., “Genetically Redirected HBV-Specific T Cells Target HBsAg-Positive Hepatocytes and Primary Lesions in HBV-Associated HCC,” Clinical and Molecular Hepatology (2024).
Citing Literature
